Sensus Healthcare Q4 revenue $12.6M, net income $4.2M; introduces recurring revenue model

Sensus Healthcare, Inc.

2023-FY EPS reported $0.03 revenue$24,405,000

Q4 revenue $12.6M (vs $13.1M YoY) but up 3x sequentially from Q3 $3.9M; net income $4.2M ($0.26 diluted EPS) vs $2.8M YoY.
Full-year 2023 net income positive at $0.03 diluted EPS; shipped 66 SRT units (33 in Q4). Cash $23.1M, no debt.
Introduced recurring revenue model for SRT-100 Vision; first placement completed with multiple in pipeline.
Appointed President & General Counsel Michael Sardano to Board of Directors.
Engaged CureRays for clinical oversight and studies to expand SRT indications beyond skin cancer and keloids.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Sensus Healthcare, Inc. reported the quarter and year ended December 31, 2023 results: revenue $12.6 million, net income $4.2 million, EPS $0.26 per diluted share.

Period: the quarter and year ended December 31, 2023
Revenue: $12.6 million
Net income: $4.2 million
EPS: $0.26 per diluted share
Result: reported results

Exact text from the filing

PRESS RELEASE, DATED FEBRUARY 8, 2024 Exhibit 99.1 Sensus Healthcare Reports Fourth Quarter and Full Year 2023 Financial Results ● Fourth quarter revenues of $12.6 million up three-fold sequentially, reflect ongoing customer adjustment to macroeconomic conditions ● Introduces recurring revenue model for the SRT-100 VisionTM (IG-SRT) to address

View on SEC.gov

Browse all earnings releases →

Sensus Healthcare, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-011598

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.